Composition which contains lactic acid bacterium as effective component and which is for preventing or ameliorating skin condition deterioration caused by abnormal proliferation of specific bacterium in skin
Provided is a pharmaceutical composition and food composition for treating or preventing a skin disease caused by abnormal growth of a skin bacterium or infection with a pathogenic microorganism. A composition comprising a lactic acid bacterium as an active ingredient, for suppressing bacterial abnormal growth, or preventing or ameliorating deterioration of skin condition caused by a bacterial abnormal growth, by oral intake thereof.
1. A method for suppressing abnormal bacterial growth in the skin, or preventing or ameliorating deterioration of a skin condition caused by abnormal bacterial growth, comprising administering orally an effective amount of a composition comprising Lactococcus lactis JCM5805 cells as an active ingredient to a human subject in need thereof, wherein the Lactococcus lactis JCM5805 cells comprise dead cells, disrupted cells, lyophilized cells, cells obtained from a culture solution, cells obtained from a culture-solution extract, treated cells, or a combination thereof, and wherein the abnormal bacterial growth is from a bacterium selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and rod-shape acne.
2. The method according to claim 1 , wherein the rod-shape acne is Propionibacterium acnes.
3. The method according to claim 1 , wherein the composition is a food composition.
4. The method according to claim 1 , wherein the composition is a pharmaceutical composition.
5. The method according to claim 3 , wherein the skin condition caused by the abnormal bacterial growth is dermatitis.
6. The method according to claim 4 , wherein the skin condition caused by the abnormal bacterial growth is selected from the group consisting of impetigo contagiosa, cellulitis, erysipelas, staphylococcal scalded skin syndrome, folliculitis, acne, furuncle, carbuncle, bacterial perionychium inflammation, chronic pyoderma, and sycosis vulgaris.
7. The method according to claim 4 , wherein the skin condition caused by the abnormal bacterial growth is dermatitis.
8. A method of promoting expression of at least one antibacterial gene in the skin of a subject, comprising orally administering to a subject in need thereof an effective amount of a composition comprising Lactococcus lactis JCM5805 cells, wherein the Lactococcus lactis JCM5805 cells comprise live cells, dead cells, disrupted cells, lyophilized cells, or a combination thereof, and wherein the at least one antibacterial gene is selected from β-defensin 1 (BD-1), β-defensin 3 (BD-3), β-defensin 14 (BD-14), and S100A8.
9. The method according to claim 8 , wherein the subject has a skin condition caused by abnormal bacterial growth.
10. The method according to claim 9 , wherein the abnormal bacterial growth is from a bacterium selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis , and rod-shape acne.
11. The method according to claim 9 , wherein the skin condition caused by the abnormal bacterial growth is dermatitis.
12. The method according to claim 9 , wherein the skin condition caused by the abnormal bacterial growth is selected from the group consisting of impetigo contagiosa, cellulitis, erysipelas, staphylococcal scalded skin syndrome, folliculitis, acne, furuncle, carbuncle, bacterial perionychium inflammation, chronic pyoderma, and sycosis vulgaris.
13. The method according to claim 8 , wherein the composition is a food composition.
14. The method according to claim 8 , wherein the composition is a pharmaceutical composition.
15. The method according to claim 8 , wherein the at least one antibacterial gene comprises at least two genes selected from β-defensin 1 (BD-1), β-defensin 3 (BD-3), β-defensin 14 (BD-14), and S100A8.
16. The method according to claim 8 , wherein the at least one antibacterial gene comprises all of β-defensin 1 (BD-1), β-defensin 3 (BD-3), β-defensin 14 (BD-14), and S100A8.